Global Atrial Fibrillation Drugs Market: Industry Analysis and Forecast (2018-2026) –by Product, Type, Route of Administration, Application, End Use, and Region.

Global Atrial Fibrillation Drugs Market: Industry Analysis and Forecast (2018-2026) –by Product, Type, Route of Administration, Application, End Use, and Region.

Market Scenario

Global Atrial Fibrillation Drugs Market was valued at US$ 14.2 Bn in 2017 and is expected to reach US$ 21.9 Bn by 2026, at a CAGR of 5.56% during a forecast period. Global Atrial Fibrillation Drugs Market Atrial fibrillation drugs market is expected to witness lucrative growth during the forecast period. The growing rate of geriatric population coupled with the increasing prevalence of valvular diseases will augment the market growth. Additionally, the increasing rate of the population suffering from diabetes is another factor driving the growth of atrial fibrillation drugs market. Increasing prevalence of cardiovascular diseases in emerging regions owing to the increase in sedentary lifestyle and increasing habit of binge eating will fuel adoption rates in developing as well as certain developed economies. However, drug side effects will be one of the major reasons hampering the adoption rates in few developing and under-developed economies. Drug side effects like severe bleeding, tiredness, etc. will continue to hinder market growth over the forecast timeframe. Similarly, a lack of awareness about recent medical drug treatments for the treatment of atrial fibrillation in certain emerging regions might hamper market growth. Anticoagulants segment is expected to dominate the atrial fibrillation drugs market during the 2018-2026. Anticoagulants were introduced with a goal to reduce the rate of stroke in individuals suffering from atrial fibrillation. Patients with atrial fibrillation should be careful for antiplatelet or anticoagulation therapy based on the patient's age and the presence of other risk factors. A significant increasinge in the incidence of atrial fibrillation associated strokes over the recent years have increased the demand for anticoagulants so, which, augmenting atrial fibrillation market growth. Oral segment is likely to account for the largest market share during the forecast period. The prevalence of atrial fibrillation across the world is growing at a rapid pace, especially with the increasing age of the population. Patients with thromboembolic stroke owing to atrial fibrillation have higher morbidity, mortality and longer hospital stays compared to patients with another form of strokes. The most prescribed drug therapies for the prevention of atrial strokes are oral drug therapies because of its effectiveness in the prevention of blood clotting so, augmenting the market growth. North America estimated to command the market during the forecast period owing to the presence of sophisticated healthcare infrastructure and higher adoption of advanced technologies in the USA and Canada. According to AtriCure, Inc.’s data, the USA has 6.0 Mn Afib patients who incurred a total cost of US$ 26.0 Bn for the disease in 2017. The U.S. holds more than US$ 1.0 Bn markets for atrial fibrillation devices. Increasing prevalence of Afib in the UK, Germany, France and other European countries is also holding substantial market share in 2017. Several players operating in the global market for atrial fibrillation drugs. The AtriCure, Inc. acquired Endoscopic Technologies, Inc. a California-based medical device manufacturing firm in order to strengthen its surgical ablation devices portfolio and to maintain a headship position in the atrial fibrillation devices market globally. The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Global Atrial Fibrillation Drugs Market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, SWOT analysis to address the question of shareholders to prioritizing the efforts and investment in the near future to the emerging segment in the Global Atrial Fibrillation Drugs Market.

Scope of the Global Atrial Fibrillation Drugs Market

Global Atrial Fibrillation Drugs Market, by Product

• Antiarrhythmic Drugs • Anticoagulant Drugs

Global Atrial Fibrillation Drugs Market, by Type

• Paroxysmal • Permanent • Persistent

Global Atrial Fibrillation Drugs Market, by Application

• Heart Rate Control • Heart Rhythm Control

Global Atrial Fibrillation Drugs Market, by Route of Administration

• Injectable • Oral

Global Atrial Fibrillation Drugs Market, by End Use

• Cardiac Centers • Hospitals • Ambulatory Surgical Centers

Global Atrial Fibrillation Drugs Market, by Region

• North America • Europe • Asia Pacific • Middle East and Africa • South America

Key players operating in Global Atrial Fibrillation Drugs Market

• Boehringer Ingelheim • Janssen Pharmaceuticals • Sanofi • ARCA Biopharma • Armetheon • Baxter • Bristol-Myers Squibb • ChanRx • Daiichi Sankyo • Gilead Sciences • HUYA Biosciences • Menarini • Pfizer • Pierre Fabre • Servier • Xention Global Central Fill Pharmacy Automation Market

Table of Contents

Global Atrial Fibrillation Drugs Market

1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Atrial Fibrillation Drugs Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Global Atrial Fibrillation Drugs Market Industry Trends and Emerging Technologies 4.8. Global Atrial Fibrillation Drugs Market Competitive Landscape 5. Supply Side and Demand Side Indicators 6. Global Atrial Fibrillation Drugs Market Analysis and Forecast 6.1. Global Atrial Fibrillation Drugs Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Atrial Fibrillation Drugs Market Analysis and Forecast, by Product 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Atrial Fibrillation Drugs Market Value Share Analysis, by Product 7.4. Global Atrial Fibrillation Drugs Market Size (US$ Bn) Forecast, by Product 7.5. Global Atrial Fibrillation Drugs Market Analysis, by Product 7.6. Global Atrial Fibrillation Drugs Market Attractiveness Analysis, by Product 8. Global Atrial Fibrillation Drugs Market Analysis and Forecast, by End Use 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Atrial Fibrillation Drugs Market Value Share Analysis, by End Use 8.4. Global Atrial Fibrillation Drugs Market Size (US$ Bn) Forecast, by End Use 8.5. Global Atrial Fibrillation Drugs Market Analysis, by End Use 8.6. Global Atrial Fibrillation Drugs Market Attractiveness Analysis, by End Use 9. Global Atrial Fibrillation Drugs Market Analysis and Forecast, by Type 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Atrial Fibrillation Drugs Market Value Share Analysis, by Type 9.4. Global Atrial Fibrillation Drugs Market Size (US$ Bn) Forecast, by Type 9.5. Global Atrial Fibrillation Drugs Market Analysis, by Type 9.6. Global Atrial Fibrillation Drugs Market Attractiveness Analysis, by Type 10. Global Atrial Fibrillation Drugs Market Analysis and Forecast, by Route of Administration 10.1. Introduction and Definition 10.2. Key Findings 10.3. Global Atrial Fibrillation Drugs Market Value Share Analysis, by Route of Administration 10.4. Global Atrial Fibrillation Drugs Market Size (US$ Bn) Forecast, by Route of Administration 10.5. Global Atrial Fibrillation Drugs Market Analysis, by Route of Administration 10.6. Global Atrial Fibrillation Drugs Market Attractiveness Analysis, by Route of Administration 11. Global Atrial Fibrillation Drugs Market Analysis and Forecast, by Application 11.1. Introduction and Definition 11.2. Key Findings 11.3. Global Atrial Fibrillation Drugs Market Value Share Analysis, by Application 11.4. Global Atrial Fibrillation Drugs Market Size (US$ Bn) Forecast, by Application 11.5. Global Atrial Fibrillation Drugs Market Analysis, by Application 11.6. Global Atrial Fibrillation Drugs Market Attractiveness Analysis, by Application 12. Global Atrial Fibrillation Drugs Market Analysis, by Region 12.1. Global Atrial Fibrillation Drugs Market Value Share Analysis, by Region 12.2. Global Atrial Fibrillation Drugs Market Size (US$ Bn) Forecast, by Region 12.3. Global Atrial Fibrillation Drugs Market Attractiveness Analysis, by Region 13. North America Atrial Fibrillation Drugs Market Analysis 13.1. Key Findings 13.2. North America Atrial Fibrillation Drugs Market Overview 13.3. North America Atrial Fibrillation Drugs Market Value Share Analysis, by Product 13.4. North America Atrial Fibrillation Drugs Market Forecast, by Product 13.4.1. Antiarrhythmic Drugs 13.4.2. Anticoagulant Drugs 13.5. North America Atrial Fibrillation Drugs Market Value Share Analysis, by End Use 13.6. North America Atrial Fibrillation Drugs Market Forecast, by End Use 13.6.1. Cardiac Centers 13.6.2. Hospitals 13.6.3. Ambulatory Surgical Centers 13.7. North America Atrial Fibrillation Drugs Market Value Share Analysis, by Type 13.8. North America Atrial Fibrillation Drugs Market Forecast, by Type 13.8.1. Paroxysmal 13.8.2. Permanent 13.8.3. Persistent 13.9. North America Atrial Fibrillation Drugs Market Value Share Analysis, by Route of Administration 13.10. North America Atrial Fibrillation Drugs Market Forecast, by Route of Administration 13.10.1. Injectable 13.10.2. Oral 13.11. North America Atrial Fibrillation Drugs Market Value Share Analysis, by Application 13.12. North America Atrial Fibrillation Drugs Market Forecast, by Application 13.12.1. Heart Rate Control 13.12.2. Heart Rhythm Control 13.13. North America Atrial Fibrillation Drugs Market Value Share Analysis, by Country 13.14. North America Atrial Fibrillation Drugs Market Forecast, by Country 13.14.1. U.S. 13.14.2. Canada 13.15. North America Atrial Fibrillation Drugs Market Analysis, by Country 13.16. U.S. Atrial Fibrillation Drugs Market Forecast, by Product 13.16.1. Antiarrhythmic Drugs 13.16.2. Anticoagulant Drugs 13.17. U.S. Atrial Fibrillation Drugs Market Forecast, by End Use 13.17.1. Cardiac Centers 13.17.2. Hospitals 13.17.3. Ambulatory Surgical Centers 13.18. U.S. Atrial Fibrillation Drugs Market Forecast, by Type 13.18.1. Paroxysmal 13.18.2. Permanent 13.18.3. Persistent 13.19. U.S. Atrial Fibrillation Drugs Market Forecast, by Route of Administration 13.19.1. Injectable 13.19.2. Oral 13.20. U.S. Atrial Fibrillation Drugs Market Forecast, by Application 13.20.1. Heart Rate Control 13.20.2. Heart Rhythm Control 13.21. Canada Atrial Fibrillation Drugs Market Forecast, by Product 13.21.1. Antiarrhythmic Drugs 13.21.2. Anticoagulant Drugs 13.22. Canada Atrial Fibrillation Drugs Market Forecast, by End Use 13.22.1. Cardiac Centers 13.22.2. Hospitals 13.22.3. Ambulatory Surgical Centers 13.23. Canada Atrial Fibrillation Drugs Market Forecast, by Type 13.23.1. Paroxysmal 13.23.2. Permanent 13.23.3. Persistent 13.24. Canada Atrial Fibrillation Drugs Market Forecast, by Route of Administration 13.24.1. Injectable 13.24.2. Oral 13.25. Canada Atrial Fibrillation Drugs Market Forecast, by Application 13.25.1. Heart Rate Control 13.25.2. Heart Rhythm Control 13.26. North America Atrial Fibrillation Drugs Market Attractiveness Analysis 13.26.1. By Product 13.26.2. By End Use 13.26.3. By Type 13.26.4. By Route of Administration 13.26.5. By Application 13.27. PEST Analysis 13.28. Key Trends 13.29. Key Developments 14. Europe Atrial Fibrillation Drugs Market Analysis 14.1. Key Findings 14.2. Europe Atrial Fibrillation Drugs Market Overview 14.3. Europe Atrial Fibrillation Drugs Market Value Share Analysis, by Product 14.4. Europe Atrial Fibrillation Drugs Market Forecast, by Product 14.4.1. Antiarrhythmic Drugs 14.4.2. Anticoagulant Drugs 14.5. Europe Atrial Fibrillation Drugs Market Value Share Analysis, by End Use 14.6. Europe Atrial Fibrillation Drugs Market Forecast, by End Use 14.6.1. Cardiac Centers 14.6.2. Hospitals 14.6.3. Ambulatory Surgical Centers 14.7. Europe Atrial Fibrillation Drugs Market Value Share Analysis, by Type 14.8. Europe Atrial Fibrillation Drugs Market Forecast, by Type 14.8.1. Paroxysmal 14.8.2. Permanent 14.8.3. Persistent 14.9. Europe Atrial Fibrillation Drugs Market Value Share Analysis, by Route of Administration 14.10. Europe Atrial Fibrillation Drugs Market Forecast, by Route of Administration 14.10.1. Injectable 14.10.2. Oral 14.11. Europe Atrial Fibrillation Drugs Market Value Share Analysis, by Application 14.12. Europe Atrial Fibrillation Drugs Market Forecast, by Application 14.12.1. Heart Rate Control 14.12.2. Heart Rhythm Control 14.13. Europe Atrial Fibrillation Drugs Market Value Share Analysis, by Country 14.14. Europe Atrial Fibrillation Drugs Market Forecast, by Country 14.14.1. Germany 14.14.2. U.K. 14.14.3. France 14.14.4. Italy 14.14.5. Spain 14.14.6. Rest of Europe 14.15. Europe Atrial Fibrillation Drugs Market Analysis, by Country 14.16. Germany Atrial Fibrillation Drugs Market Forecast, by Product 14.16.1. Antiarrhythmic Drugs 14.16.2. Anticoagulant Drugs 14.17. Germany Atrial Fibrillation Drugs Market Forecast, by End Use 14.17.1. Cardiac Centers 14.17.2. Hospitals 14.17.3. Ambulatory Surgical Centers 14.18. Germany Atrial Fibrillation Drugs Market Forecast, by Type 14.18.1. Paroxysmal 14.18.2. Permanent 14.18.3. Persistent 14.19. Germany Atrial Fibrillation Drugs Market Forecast, by Route of Administration 14.19.1. Injectable 14.19.2. Oral 14.20. Germany Atrial Fibrillation Drugs Market Forecast, by Application 14.20.1. Heart Rate Control 14.20.2. Heart Rhythm Control 14.21. U.K. Atrial Fibrillation Drugs Market Forecast, by Product 14.21.1. Antiarrhythmic Drugs 14.21.2. Anticoagulant Drugs 14.22. U.K. Atrial Fibrillation Drugs Market Forecast, by End Use 14.22.1. Cardiac Centers 14.22.2. Hospitals 14.22.3. Ambulatory Surgical Centers 14.23. U.K. Atrial Fibrillation Drugs Market Forecast, by Type 14.23.1. Paroxysmal 14.23.2. Permanent 14.23.3. Persistent 14.24. U.K. Atrial Fibrillation Drugs Market Forecast, by Route of Administration 14.24.1. Injectable 14.24.2. Oral 14.25. U.K. Atrial Fibrillation Drugs Market Forecast, by Application 14.25.1. Heart Rate Control 14.25.2. Heart Rhythm Control 14.26. France Atrial Fibrillation Drugs Market Forecast, by Product 14.26.1. Antiarrhythmic Drugs 14.26.2. Anticoagulant Drugs 14.27. France Atrial Fibrillation Drugs Market Forecast, by End Use 14.27.1. Cardiac Centers 14.27.2. Hospitals 14.27.3. Ambulatory Surgical Centers 14.28. France Atrial Fibrillation Drugs Market Forecast, by Type 14.28.1. Paroxysmal 14.28.2. Permanent 14.28.3. Persistent 14.29. France Atrial Fibrillation Drugs Market Forecast, by Route of Administration 14.29.1. Injectable 14.29.2. Oral 14.30. France Atrial Fibrillation Drugs Market Forecast, by Application 14.30.1. Heart Rate Control 14.30.2. Heart Rhythm Control 14.31. Italy Atrial Fibrillation Drugs Market Forecast, by Product 14.31.1. Antiarrhythmic Drugs 14.31.2. Anticoagulant Drugs 14.32. Italy Atrial Fibrillation Drugs Market Forecast, by End Use 14.32.1. Cardiac Centers 14.32.2. Hospitals 14.32.3. Ambulatory Surgical Centers 14.33. Italy Atrial Fibrillation Drugs Market Forecast, by Type 14.33.1. Paroxysmal 14.33.2. Permanent 14.33.3. Persistent 14.34. Italy Atrial Fibrillation Drugs Market Forecast, by Route of Administration 14.34.1. Injectable 14.34.2. Oral 14.35. Italy Atrial Fibrillation Drugs Market Forecast, by Application 14.35.1. Heart Rate Control 14.35.2. Heart Rhythm Control 14.36. Spain Atrial Fibrillation Drugs Market Forecast, by Product 14.36.1. Antiarrhythmic Drugs 14.36.2. Anticoagulant Drugs 14.37. Spain Atrial Fibrillation Drugs Market Forecast, by End Use 14.37.1. Cardiac Centers 14.37.2. Hospitals 14.37.3. Ambulatory Surgical Centers 14.38. Spain Atrial Fibrillation Drugs Market Forecast, by Type 14.38.1. Paroxysmal 14.38.2. Permanent 14.38.3. Persistent 14.39. Spain Atrial Fibrillation Drugs Market Forecast, by Route of Administration 14.39.1. Injectable 14.39.2. Oral 14.40. Spain Atrial Fibrillation Drugs Market Forecast, by Application 14.40.1. Heart Rate Control 14.40.2. Heart Rhythm Control 14.41. Rest of Europe Atrial Fibrillation Drugs Market Forecast, by Product 14.41.1. Antiarrhythmic Drugs 14.41.2. Anticoagulant Drugs 14.42. Rest of Europe Atrial Fibrillation Drugs Market Forecast, by End Use 14.42.1. Cardiac Centers 14.42.2. Hospitals 14.42.3. Ambulatory Surgical Centers 14.43. Rest of Europe Atrial Fibrillation Drugs Market Forecast, by Type 14.43.1. Paroxysmal 14.43.2. Permanent 14.43.3. Persistent 14.44. Rest Of Europe Atrial Fibrillation Drugs Market Forecast, by Route of Administration 14.44.1. Injectable 14.44.2. Oral 14.45. Rest Of Europe Atrial Fibrillation Drugs Market Forecast, by Application 14.45.1. Heart Rate Control 14.45.2. Heart Rhythm Control 14.46. Europe Atrial Fibrillation Drugs Market Attractiveness Analysis 14.46.1. By Product 14.46.2. By End Use 14.46.3. By Type 14.46.4. By Route of Administration 14.46.5. By Application 14.47. PEST Analysis 14.48. Key Trends 14.49. Key Developments 15. Asia Pacific Atrial Fibrillation Drugs Market Analysis 15.1. Key Findings 15.2. Asia Pacific Atrial Fibrillation Drugs Market Overview 15.3. Asia Pacific Atrial Fibrillation Drugs Market Value Share Analysis, by Product 15.4. Asia Pacific Atrial Fibrillation Drugs Market Forecast, by Product 15.4.1. Antiarrhythmic Drugs 15.4.2. Anticoagulant Drugs 15.5. Asia Pacific Atrial Fibrillation Drugs Market Value Share Analysis, by End Use 15.6. Asia Pacific Atrial Fibrillation Drugs Market Forecast, by End Use 15.6.1. Cardiac Centers 15.6.2. Hospitals 15.6.3. Ambulatory Surgical Centers 15.7. Asia Pacific Atrial Fibrillation Drugs Market Value Share Analysis, by Type 15.8. Asia Pacific Atrial Fibrillation Drugs Market Forecast, by Type 15.8.1. Paroxysmal 15.8.2. Permanent 15.8.3. Persistent 15.9. Asia Pacific Atrial Fibrillation Drugs Market Value Share Analysis, by Route of Administration 15.10. Asia Pacific Atrial Fibrillation Drugs Market Forecast, by Route of Administration 15.10.1. Injectable 15.10.2. Oral 15.11. Asia Pacific Atrial Fibrillation Drugs Market Value Share Analysis, by Application 15.12. Asia Pacific Atrial Fibrillation Drugs Market Forecast, by Application 15.12.1. Heart Rate Control 15.12.2. Heart Rhythm Control 15.13. Asia Pacific Atrial Fibrillation Drugs Market Value Share Analysis, by Country 15.14. Asia Pacific Atrial Fibrillation Drugs Market Forecast, by Country 15.14.1. China 15.14.2. India 15.14.3. Japan 15.14.4. ASEAN 15.14.5. Rest of Asia Pacific 15.15. Asia Pacific Atrial Fibrillation Drugs Market Analysis, by Country 15.16. China Atrial Fibrillation Drugs Market Forecast, by Product 15.16.1. Antiarrhythmic Drugs 15.16.2. Anticoagulant Drugs 15.17. China Atrial Fibrillation Drugs Market Forecast, by End Use 15.17.1. Cardiac Centers 15.17.2. Hospitals 15.17.3. Ambulatory Surgical Centers 15.18. China Atrial Fibrillation Drugs Market Forecast, by Type 15.18.1. Paroxysmal 15.18.2. Permanent 15.18.3. Persistent 15.19. China Atrial Fibrillation Drugs Market Forecast, by Route of Administration 15.19.1. Injectable 15.19.2. Oral 15.20. China Atrial Fibrillation Drugs Market Forecast, by Application 15.20.1. Heart Rate Control 15.20.2. Heart Rhythm Control 15.21. India Atrial Fibrillation Drugs Market Forecast, by Product 15.21.1. Antiarrhythmic Drugs 15.21.2. Anticoagulant Drugs 15.22. India Atrial Fibrillation Drugs Market Forecast, by End Use 15.22.1. Cardiac Centers 15.22.2. Hospitals 15.22.3. Ambulatory Surgical Centers 15.23. India Atrial Fibrillation Drugs Market Forecast, by Type 15.23.1. Paroxysmal 15.23.2. Permanent 15.23.3. Persistent 15.24. India Atrial Fibrillation Drugs Market Forecast, by Route of Administration 15.24.1. Injectable 15.24.2. Oral 15.25. India Atrial Fibrillation Drugs Market Forecast, by Application 15.25.1. Heart Rate Control 15.25.2. Heart Rhythm Control 15.26. Japan Atrial Fibrillation Drugs Market Forecast, by Product 15.26.1. Antiarrhythmic Drugs 15.26.2. Anticoagulant Drugs 15.27. Japan Atrial Fibrillation Drugs Market Forecast, by End Use 15.27.1. Cardiac Centers 15.27.2. Hospitals 15.27.3. Ambulatory Surgical Centers 15.28. Japan Atrial Fibrillation Drugs Market Forecast, by Type 15.28.1. Paroxysmal 15.28.2. Permanent 15.28.3. Persistent 15.29. Japan Atrial Fibrillation Drugs Market Forecast, by Route of Administration 15.29.1. Injectable 15.29.2. Oral 15.30. Japan Atrial Fibrillation Drugs Market Forecast, by Application 15.30.1. Heart Rate Control 15.30.2. Heart Rhythm Control 15.31. ASEAN Atrial Fibrillation Drugs Market Forecast, by Product 15.31.1. Antiarrhythmic Drugs 15.31.2. Anticoagulant Drugs 15.32. ASEAN Atrial Fibrillation Drugs Market Forecast, by End Use 15.32.1. Cardiac Centers 15.32.2. Hospitals 15.32.3. Ambulatory Surgical Centers 15.33. ASEAN Atrial Fibrillation Drugs Market Forecast, by Type 15.33.1. Paroxysmal 15.33.2. Permanent 15.33.3. Persistent 15.34. ASEAN Atrial Fibrillation Drugs Market Forecast, by Route of Administration 15.34.1. Injectable 15.34.2. Oral 15.35. ASEAN Atrial Fibrillation Drugs Market Forecast, by Application 15.35.1. Heart Rate Control 15.35.2. Heart Rhythm Control 15.36. Rest of Asia Pacific Atrial Fibrillation Drugs Market Forecast, by Product 15.36.1. Antiarrhythmic Drugs 15.36.2. Anticoagulant Drugs 15.37. Rest of Asia Pacific Atrial Fibrillation Drugs Market Forecast, by End Use 15.37.1. Cardiac Centers 15.37.2. Hospitals 15.37.3. Ambulatory Surgical Centers 15.38. Rest of Asia Pacific Atrial Fibrillation Drugs Market Forecast, by Type 15.38.1. Paroxysmal 15.38.2. Permanent 15.38.3. Persistent 15.39. Rest of Asia Pacific Atrial Fibrillation Drugs Market Forecast, by Route of Administration 15.39.1. Injectable 15.39.2. Oral 15.40. Rest of Asia Pacific Atrial Fibrillation Drugs Market Forecast, by Application 15.40.1. Heart Rate Control 15.40.2. Heart Rhythm Control 15.41. Asia Pacific Atrial Fibrillation Drugs Market Attractiveness Analysis 15.41.1. By Product 15.41.2. By End Use 15.41.3. By Type 15.41.4. By Route of Administration 15.41.5. By Application 15.42. PEST Analysis 15.43. Key Trends 15.44. Key Developments 16. Middle East & Africa Atrial Fibrillation Drugs Market Analysis 16.1. Key Findings 16.2. Middle East & Africa Atrial Fibrillation Drugs Market Overview 16.3. Middle East & Africa Atrial Fibrillation Drugs Market Value Share Analysis, by Product 16.4. Middle East & Africa Atrial Fibrillation Drugs Market Forecast, by Product 16.4.1. Antiarrhythmic Drugs 16.4.2. Anticoagulant Drugs 16.5. Middle East & Africa Atrial Fibrillation Drugs Market Value Share Analysis, by End Use 16.6. Middle East & Africa Atrial Fibrillation Drugs Market Forecast, by End Use 16.6.1. Cardiac Centers 16.6.2. Hospitals 16.6.3. Ambulatory Surgical Centers 16.7. Middle East & Africa Atrial Fibrillation Drugs Market Value Share Analysis, by Type 16.8. Middle East & Africa Atrial Fibrillation Drugs Market Forecast, by Type 16.8.1. Paroxysmal 16.8.2. Permanent 16.8.3. Persistent 16.9. Middle East & Africa Atrial Fibrillation Drugs Market Value Share Analysis, by Route of Administration 16.10. Middle East & Africa Atrial Fibrillation Drugs Market Forecast, by Route of Administration 16.10.1. Injectable 16.10.2. Oral 16.11. Middle East & Africa Atrial Fibrillation Drugs Market Value Share Analysis, by Application 16.12. Middle East & Africa Atrial Fibrillation Drugs Market Forecast, by Application 16.12.1. Heart Rate Control 16.12.2. Heart Rhythm Control 16.13. Middle East & Africa Atrial Fibrillation Drugs Market Value Share Analysis, by Country 16.14. Middle East & Africa Atrial Fibrillation Drugs Market Forecast, by Country 16.14.1. GCC 16.14.2. South Africa 16.14.3. Rest of Middle East & Africa 16.15. Middle East & Africa Atrial Fibrillation Drugs Market Analysis, by Country 16.16. GCC Atrial Fibrillation Drugs Market Forecast, by Product 16.16.1. Antiarrhythmic Drugs 16.16.2. Anticoagulant Drugs 16.17. GCC Atrial Fibrillation Drugs Market Forecast, by End Use 16.17.1. Cardiac Centers 16.17.2. Hospitals 16.17.3. Ambulatory Surgical Centers 16.18. GCC Atrial Fibrillation Drugs Market Forecast, by Type 16.18.1. Paroxysmal 16.18.2. Permanent 16.18.3. Persistent 16.19. GCC Atrial Fibrillation Drugs Market Forecast, by Route of Administration 16.19.1. Injectable 16.19.2. Oral 16.20. GCC Atrial Fibrillation Drugs Market Forecast, by Application 16.20.1. Heart Rate Control 16.20.2. Heart Rhythm Control 16.21. South Africa Atrial Fibrillation Drugs Market Forecast, by Product 16.21.1. Antiarrhythmic Drugs 16.21.2. Anticoagulant Drugs 16.22. South Africa Atrial Fibrillation Drugs Market Forecast, by End Use 16.22.1. Cardiac Centers 16.22.2. Hospitals 16.22.3. Ambulatory Surgical Centers 16.23. South Africa Atrial Fibrillation Drugs Market Forecast, by Type 16.23.1. Paroxysmal 16.23.2. Permanent 16.23.3. Persistent 16.24. South Africa Atrial Fibrillation Drugs Market Forecast, by Route of Administration 16.24.1. Injectable 16.24.2. Oral 16.25. South Africa Atrial Fibrillation Drugs Market Forecast, by Application 16.25.1. Heart Rate Control 16.25.2. Heart Rhythm Control 16.26. Rest of Middle East & Africa Atrial Fibrillation Drugs Market Forecast, by Product 16.26.1. Antiarrhythmic Drugs 16.26.2. Anticoagulant Drugs 16.27. Rest of Middle East & Africa Atrial Fibrillation Drugs Market Forecast, by End Use 16.27.1. Cardiac Centers 16.27.2. Hospitals 16.27.3. Ambulatory Surgical Centers 16.28. Rest of Middle East & Africa Atrial Fibrillation Drugs Market Forecast, by Type 16.28.1. Paroxysmal 16.28.2. Permanent 16.28.3. Persistent 16.29. Rest of Middle East & Africa Atrial Fibrillation Drugs Market Forecast, by Route of Administration 16.29.1. Injectable 16.29.2. Oral 16.30. Rest of Middle East & Africa Atrial Fibrillation Drugs Market Forecast, by Application 16.30.1. Heart Rate Control 16.30.2. Heart Rhythm Control 16.31. Middle East & Africa Atrial Fibrillation Drugs Market Attractiveness Analysis 16.31.1. By Product 16.31.2. By End Use 16.31.3. By Type 16.31.4. By Route of Administration 16.31.5. By Application 16.32. PEST Analysis 16.33. Key Trends 16.34. Key Developments 17. South America Atrial Fibrillation Drugs Market Analysis 17.1. Key Findings 17.2. South America Atrial Fibrillation Drugs Market Overview 17.3. South America Atrial Fibrillation Drugs Market Value Share Analysis, by Product 17.4. South America Atrial Fibrillation Drugs Market Forecast, by Product 17.4.1. Antiarrhythmic Drugs 17.4.2. Anticoagulant Drugs 17.5. South America Atrial Fibrillation Drugs Market Value Share Analysis, by End Use 17.6. South America Atrial Fibrillation Drugs Market Forecast, by End Use 17.6.1. Cardiac Centers 17.6.2. Hospitals 17.6.3. Ambulatory Surgical Centers 17.7. South America Atrial Fibrillation Drugs Market Value Share Analysis, by Type 17.8. South America Atrial Fibrillation Drugs Market Forecast, by Type 17.8.1. Paroxysmal 17.8.2. Permanent 17.8.3. Persistent 17.9. South America Atrial Fibrillation Drugs Market Value Share Analysis, by Route of Administration 17.10. South America Atrial Fibrillation Drugs Market Forecast, by Route of Administration 17.10.1. Injectable 17.10.2. Oral 17.11. South America Atrial Fibrillation Drugs Market Value Share Analysis, by Application 17.12. South America Atrial Fibrillation Drugs Market Forecast, by Application 17.12.1. Heart Rate Control 17.12.2. Heart Rhythm Control 17.13. South America Atrial Fibrillation Drugs Market Value Share Analysis, by Country 17.14. South America Atrial Fibrillation Drugs Market Forecast, by Country 17.14.1. Brazil 17.14.2. Mexico 17.14.3. Rest of South America 17.15. South America Atrial Fibrillation Drugs Market Analysis, by Country 17.16. Brazil Atrial Fibrillation Drugs Market Forecast, by Product 17.16.1. Antiarrhythmic Drugs 17.16.2. Anticoagulant Drugs 17.17. Brazil Atrial Fibrillation Drugs Market Forecast, by End Use 17.17.1. Cardiac Centers 17.17.2. Hospitals 17.17.3. Ambulatory Surgical Centers 17.18. Brazil Atrial Fibrillation Drugs Market Forecast, by Type 17.18.1. Paroxysmal 17.18.2. Permanent 17.18.3. Persistent 17.19. Brazil Atrial Fibrillation Drugs Market Forecast, by Route of Administration 17.19.1. Injectable 17.19.2. Oral 17.20. Brazil Atrial Fibrillation Drugs Market Forecast, by Application 17.20.1. Heart Rate Control 17.20.2. Heart Rhythm Control 17.21. Mexico Atrial Fibrillation Drugs Market Forecast, by Product 17.21.1. Antiarrhythmic Drugs 17.21.2. Anticoagulant Drugs 17.22. Mexico Atrial Fibrillation Drugs Market Forecast, by End Use 17.22.1. Cardiac Centers 17.22.2. Hospitals 17.22.3. Ambulatory Surgical Centers 17.23. Mexico Atrial Fibrillation Drugs Market Forecast, by Type 17.23.1. Paroxysmal 17.23.2. Permanent 17.23.3. Persistent 17.24. Mexico Atrial Fibrillation Drugs Market Forecast, by Route of Administration 17.24.1. Injectable 17.24.2. Oral 17.25. Mexico Atrial Fibrillation Drugs Market Forecast, by Application 17.25.1. Heart Rate Control 17.25.2. Heart Rhythm Control 17.26. Rest of South America Atrial Fibrillation Drugs Market Forecast, by Product 17.26.1. Antiarrhythmic Drugs 17.26.2. Anticoagulant Drugs 17.27. Rest of South America Atrial Fibrillation Drugs Market Forecast, by End Use 17.27.1. Cardiac Centers 17.27.2. Hospitals 17.27.3. Ambulatory Surgical Centers 17.28. Rest of South America Atrial Fibrillation Drugs Market Forecast, by Type 17.28.1. Paroxysmal 17.28.2. Permanent 17.28.3. Persistent 17.29. Rest of South America Atrial Fibrillation Drugs Market Forecast, by Route of Administration 17.29.1. Injectable 17.29.2. Oral 17.30. Rest of South America Atrial Fibrillation Drugs Market Forecast, by Application 17.30.1. Heart Rate Control 17.30.2. Heart Rhythm Control 17.31. South America Atrial Fibrillation Drugs Market Attractiveness Analysis 17.31.1. By Product 17.31.2. By End Use 17.31.3. By Type 17.31.4. By Route of Administration 17.31.5. By Application 17.32. PEST Analysis 17.33. Key Trends 17.34. Key Developments 18. Company Profiles 18.1. Market Share Analysis, by Company 18.2. Competition Matrix 18.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 18.2.2. New Product Launches and Product Enhancements 18.2.3. Market Consolidation 18.2.3.1. M&A by Regions, Investment and Applications 18.2.3.2. M&A Key Players, Forward Integration and Backward Integration 18.3. Company Profiles: Key Players 18.3.1. Boehringer Ingelheim. 18.3.1.1. Company Overview 18.3.1.2. Financial Overview 18.3.1.3. Product Portfolio 18.3.1.4. Business Strategy 18.3.1.5. Recent Developments 18.3.1.6. Company Footprint 18.3.2. Janssen Pharmaceuticals 18.3.3. Sanofi 18.3.4. ARCA Biopharma 18.3.5. Armetheon 18.3.6. Baxter 18.3.7. Bristol-Myers Squibb 18.3.8. ChanRx 18.3.9. Daiichi Sankyo 18.3.10. Gilead Sciences 18.3.11. HUYA Biosciences 18.3.12. Menarini 18.3.13. Pfizer 18.3.14. Pierre Fabre 18.3.15. Servier 18.3.16. Xention 19. Primary Key Insights

Inquiry Before Buying

Request Sample

About This Report

Report ID31035
Category Healthcare
Publisher Name
No of Pages
Total Views
Published DateJune 2019
Contact Us
Call Now